23/01/2025  08:08:08 Chg. +0.35 Volume Bid20:59:23 Demandez à20:59:23 Capitalisation boursière Dividende Y. Rapport P/E
130.90EUR +0.27% 0
Chiffrre d'affaires: 0.00
130.85Bid taille: 40 131.50Ask la taille: 40 204.11 Mrd.EUR - -

Description de l'entreprise

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
 

Conseil d'administration & Conseil de surveillance

PDG
Pascal Soriot
Conseil d'administration
Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Jeff Pott, Iskra Reic, Sharon Barr
Conseil de surveillance
Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg, Anna Manz, Rene Haas
 

Données de l'entreprise

Nom: AstraZeneca plc
Adresse: 1 Francis Crick Avenue Cambridge Biomedical Campus,Cambridge, CB2 0AA United Kingdom
Téléphone: 0800 783 0033
Fax: +44-20-7604-8151
Courriel: Medical.InformationU...eca.com Medical.InformationUK@astrazeneca.com
Internet: www.astrazeneca.com
Industrie: Healthcare
Secteur: Pharmaceutical Industry
Sous-secteur: Pharmaceuticals
Fin de l'exercice financier: 31/12
Flotte libre: -
IPO date: 06/04/1999

Relations avec les investisseurs

Nom: Andy Barnett
Téléphone IR: +44 (0)20 3749 5000
IR-Fax: -
E-mail IR: CorporateAccess@astrazeneca

Calendrier de l'entreprise

CW 6 | 06/02/2025 4th Quarter/Annual Report
CW 18 | 29/04/2025 Interim Report 1st Quarter/3 Months
 

Principaux actionnaires

Autres
 
77.64%
BlackRock, Inc.
 
6.51%
Wellington Management Company LLP
 
4.20%
Wellington Management Group LLP
 
4.20%
The Capital Group Companies, Inc
 
4.12%
Investor AB
 
3.33%